Genetic engineering of primary human mesenchymal stromal cells using the CRISPR/Cas9 synergistic activation mediator
Madeleine C. Killer, Cornelia Brendel(Philipps University of Marburg), Xiaoqing Zhang(Tongji University), Miriam Frech, Andreas Neubauer(RWTH Aachen University), Cornelia Kasper(BOKU University), Till Adhikary(Institute of Molecular Biology)
Cited by 0
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573